Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, Von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Wolff D, Schroers R, Borchmann P, Rejeski K, Hanoun C, Lengerke C, Thomas S, Beelen DW, Kroeger N, Bethge WA (2021)


Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

DOI: 10.1182/blood-2021-151469

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Dreger, P., Schubert, M.-L., Holtick, U., Subklewe, M., Von Bastian, T., Ayuk, F.A.,... Bethge, W.A. (2021). Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis. In BLOOD. WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Dreger, Peter, et al. "Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis." Proceedings of the BLOOD WASHINGTON: AMER SOC HEMATOLOGY, 2021.

BibTeX: Download